Hereditary Angioedema (HAE) Clinical Trials

A listing of 5 Hereditary Angioedema (HAE) clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Hereditary Angioedema (HAE)

1 - 5 of 5

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 5 active clinical trials seeking participants for Hereditary Angioedema (HAE) research studies. The states with the highest number of trials for Hereditary Angioedema (HAE) participants are California, Ohio, Texas and Pennsylvania.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Phase 2 in Adult Subjects With Hereditary Angioedema

NCT06846398

Recruiting

A Phase 2 in Adult Subjects with Hereditary Angioedema

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

06/25/2025

Locations: Raffi Tachdjian, MD Inc, Santa Monica, California +18 locations

Conditions: Hereditary Angioedema (HAE)

Learn More ›

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754

Recruiting

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.

Gender:

ALL

Ages:

12 years and above

Trial Updated:

06/23/2025

Locations: Study Site, Little Rock, Arkansas +44 locations

Study Site, Little Rock, Arkansas

Study site, Santa Monica, California

Study site, Walnut Creek, California

Study Site, Wheaton, Maryland

Study Site, Saint Louis, Missouri

Study Site, Corrientes, Not set

Study Site, Sofia, Not set

Study Site, Edmonton, Not set

Study Site, Ottawa, Not set

Study Site, Grenoble, Not set

Study Site, Lille, Not set

Study Site, Berlin, Not set

Study Site, Hongkong, Not set

Study Site, Budapest, Not set

Study Site, Dublin, Not set

Study Site, Milan, Not set

Study Site, Padova, Not set

Study Site, Tokyo, Not set

Study Site, Seoul, Not set

Study Site, Suwon, Not set

Study Site, Auckland, Not set

Study Site, Kraków, Not set

Study Site, San Juan, Not set

Study Site, Sangeorgiu de Mures, Not set

Study Site, Singapore, Not set

Study Site, Martin, Not set

Study Site, Cape Town, Not set

Study Site, Barcelona, Not set

Study Site, Seville, Not set

Study Site, Ankara, Not set

Study Site, İzmir, Not set

Study site, London, England

Study Site, Birmingham, Not set

Study Site, Bristol, Not set

Study Site, Cambridge, Not set

Study Site, Frimley, Not set

Study Site, Leeds, Not set

Study Site, London, Not set

Study Site, Oxford, Not set

Study site, Plymouth, Not set

Study Site, Southampton, Not set

Conditions: Hereditary Angioedema (HAE)

Learn More ›

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881

Recruiting

This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema

Gender:

ALL

Ages:

12 years and above

Trial Updated:

06/23/2025

Locations: Study Site, Santa Monica, California +14 locations

Conditions: Hereditary Angioedema (HAE)

Learn More ›

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823

Recruiting

This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.

Gender:

ALL

Ages:

12 years and above

Trial Updated:

06/23/2025

Locations: Site 9, Birmingham, Alabama +13 locations

Conditions: Hereditary Angioedema (HAE)

Learn More ›

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

NCT07046806

Recruiting

To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

06/23/2025

Locations: Institute For Asthma & Allergy, Wheaton, Maryland

Conditions: Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency

Learn More ›

1 - 5 of 5